Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
RC298
- Development stage
- Preclinical
- Lead developer
- RemeGen
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Administration
- Subcutaneous
01
Overview
RC298 is an investigational, next-generation, long-acting dual BAFF/APRIL inhibitor developed by RemeGen and licensed to Vor Bio for development and commercialization outside of Greater China. It is an engineered TACI-Fc fusion protein designed to simultaneously inhibit B-cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), which are key regulators of pathogenic B-cell and plasma-cell biology. By blocking these pathways, RC298 aims to reduce autoreactive B cells and autoantibody production to treat various autoimmune diseases. The molecule is engineered for optimized functional potency and pharmacokinetics, with a structural design intended to enable extended dosing intervals. It is currently in IND-enabling preclinical development, with an investigational new drug (IND) submission in China anticipated in the first half of 2027.
02
Targets
Beyond the preview
Go deeper on RC298.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on RC298.
Work on RC298? Claim this page to correct or add information. Claim this page